新生儿阿兹罗米辛暴露和儿童成长:随机对照试验的长期随访
Mamadou Bountogo1, Lucienne Ouermi1, Clarisse Dah1
1Centre de Recherche en Sante de Nouna, Nouna, Burkina Faso.
The American journal of tropical medicine and hygiene
|July 16, 2024
概括
新生儿阿齐思罗米 (一次剂量) 没有影响到4岁以下的儿童生长. 这项研究没有发现婴儿早期暴露于抗生素的长期生长益处或危害的证据.
科学领域:
- 儿科 儿科 儿科
- 传染性疾病 传染性疾病
- 全球健康 全球健康
背景情况:
- 世界卫生组织正在评估单剂量阿齐思罗米的预防儿童死亡率.
- 对于婴儿早期暴露于抗生素的意想不到的长期影响存在担忧.
研究的目的:
- 评估新生儿阿齐思罗米辛暴露对4岁以下儿童生长的长期影响.
- 为了评估在新生儿中阿齐思罗米与安慰剂的试验后儿童的人体测量结果.
主要方法:
- 从新生儿死亡率预防试验中随机抽样儿童的长期随访.
- 接受新生儿阿齐思罗米和接受安慰剂的婴儿之间的人类测量结果的比较.
主要成果:
- 在4岁时,在阿齐思罗米和安慰剂组之间没有观察到任何人类测量结果的显著差异.
- 新生儿单剂量阿齐思罗米辛暴露不会导致儿童生长的可检测差异.
结论:
- 早期生活,单剂量阿齐思罗米暴露似乎没有对儿童生长产生长期有害或有益的影响.
- 结果不支持对新生儿阿齐思罗米辛使用增长障碍或增强的担忧.
相关概念视频
Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Microbiota Modulation by Antibiotics
Antibiotics have revolutionized modern medicine by saving countless lives from bacterial infections. However, their widespread use has inadvertently harmed the delicate balance of the human gut microbiota. The gut microbiota, a complex community of bacteria, archaea, viruses, and fungi, plays a vital role in regulating metabolism, immune responses, and maintaining intestinal health. Antibiotics, especially broad-spectrum types, disrupt this ecosystem by eradicating both harmful and beneficial...


